Iron metabolism

Lucky Iron Fish receives $250k in funding to help address iron deficiency anemia in Benin.

Retrieved on: 
Wednesday, June 30, 2021
Mineral deficiencies, Nutrition, Chemistry, Iron metabolism, Physical sciences, Iron-deficiency anemia, Lucky iron fish, Iron deficiency, Iron, Anemia

Toronto, June 30, 2021 (GLOBE NEWSWIRE) -- Lucky Iron Fish Enterprise (LIFe) is an impact-driven company that is on a mission to tackle iron deficiency globally using their innovative solutions designed to make iron intake more accessible to more people.

Key Points: 
  • Toronto, June 30, 2021 (GLOBE NEWSWIRE) -- Lucky Iron Fish Enterprise (LIFe) is an impact-driven company that is on a mission to tackle iron deficiency globally using their innovative solutions designed to make iron intake more accessible to more people.
  • For this project, LIFe will be working with their long-termpartners at CARE Benin .With the help of the $250,000 funding, they will provide nutrition workshops and introduce the Lucky Iron Fish as a recommended addition to daily cooking in order to reduce prevalence of iron deficiency anemia.
  • Iron deficiency is a global health issue that impacts 1 out of 3 individuals (2+ billion worldwide), with women, girls, and children impacted at a disproportionately higher rate.
  • In Benin alone, 62% of children under 5 and 47% of females of reproductive age suffer from iron deficiency anemia.

Keros Therapeutics Presents Preclinical Data from ALK2 and KER-050 Hematology Programs at the European Hematology Association EHA2021 Virtual Congress

Retrieved on: 
Friday, June 11, 2021
Branches of biology, Iron metabolism, Medical specialties, Clinical medicine, Blood proteins, Hepatology, Peptide hormones, Hepcidin, Iron overload, Erythropoietin

Poster presentation demonstrates that KER-050 had effects on multiple stages of erythroblast maturation (both early- and late-stage) and increased circulating erythropoietin in preclinical models.

Key Points: 
  • Poster presentation demonstrates that KER-050 had effects on multiple stages of erythroblast maturation (both early- and late-stage) and increased circulating erythropoietin in preclinical models.
  • We are pleased to be able to present multiple posters at this years EHA2021 Virtual Congress.
  • Our preclinical studies continue to elucidate the relationship between ALK2 inhibition, hepcidin and serum iron.
  • In addition, the data suggests that ALK2 inhibition has the potential to mobilize and reduce tissue iron in diseases of iron overload, said Jasbir S. Seehra, Ph.D., Chief Executive Officer of Keros.

European Hematology Association - Mutations in PIGA Cause a New Form of Juvenile Hemochromatosis

Retrieved on: 
Friday, June 11, 2021
Iron metabolism, PIGA, Iron overload, Clinical medicine, Medical specialties, Medicine, Hemochromatosis type 4

In addition to the frequent late-onset subtype of hemochromatosis, rare forms have been described with severe iron accumulation in children.

Key Points: 
  • In addition to the frequent late-onset subtype of hemochromatosis, rare forms have been described with severe iron accumulation in children.
  • Our work identifies a novel subtype of juvenile hemochromatosis due to mutations in the phosphatidylinositol glycan class A (PIGA) gene, which anchors proteins to the cell membrane.
  • Systemic iron overload and PIGA mutations were diagnosed in three juvenile patients with neurological deficits.
  • This new link advocates for the need for clinical assessment of potential iron overload in patients with germline PIGA mutations.

European Hematology Association - Mutations in PIGA Cause a New Form of Juvenile Hemochromatosis

Retrieved on: 
Friday, June 11, 2021
Iron metabolism, PIGA, Iron overload, Clinical medicine, Medical specialties, Medicine, Hemochromatosis type 4

In addition to the frequent late-onset subtype of hemochromatosis, rare forms have been described with severe iron accumulation in children.

Key Points: 
  • In addition to the frequent late-onset subtype of hemochromatosis, rare forms have been described with severe iron accumulation in children.
  • Our work identifies a novel subtype of juvenile hemochromatosis due to mutations in the phosphatidylinositol glycan class A (PIGA) gene, which anchors proteins to the cell membrane.
  • Systemic iron overload and PIGA mutations were diagnosed in three juvenile patients with neurological deficits.
  • This new link advocates for the need for clinical assessment of potential iron overload in patients with germline PIGA mutations.

2021 Market Report on Hepcidin Drugs in Development - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 3, 2021
Health, Pharmaceutical, Medical specialties, Branches of biology, Iron metabolism, Blood proteins, Hepatology, Peptide hormones, Hepcidin, Immune system, Hamp, Antimicrobial peptides, Liver, HEPC

The "Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Drugs in Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Drugs in Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to this report the pipeline Target constitutes close to 5 molecules.
  • Hepcidin is a protein encoded by the HAMP gene.
  • It also reviews key players involved in Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics development with respective active and dormant or discontinued projects.

Disc Medicine to Present at the European Hematology Association (EHA) 2021 Virtual Congress

Retrieved on: 
Monday, May 24, 2021
Hepatology, Hepcidin, Iron metabolism, EHA, European Hematology Association, Branches of biology, Medicine, Health care

CAMBRIDGE, Mass., May 24, 2021 /PRNewswire/ --Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, today announced that preclinical data of its hepcidin induction program will be presented at the upcoming European Hematology Association (EHA) 2021 Virtual Congress, which will be held from June 9-17.

Key Points: 
  • CAMBRIDGE, Mass., May 24, 2021 /PRNewswire/ --Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, today announced that preclinical data of its hepcidin induction program will be presented at the upcoming European Hematology Association (EHA) 2021 Virtual Congress, which will be held from June 9-17.
  • Details of the presentations are as follows:
    The e-poster presentation will be made available as of Friday, June 11, 2021 (09:00 CEST) and will be accessible for on-demand viewing until August 15, 2021.
  • The abstract is currently available online on EHA2021 Virtual Congress Platform.
  • Disc Medicine is a biopharmaceutical company dedicated to transforming the lives of patients with hematologic disorders.

Cerecor Doses First Patient in a Phase 1b Proof-of-Concept Clinical Trial of CERC-007 for the Treatment of Adult Onset Still’s Disease

Retrieved on: 
Wednesday, May 5, 2021
Medical specialties, Clinical medicine, Medicine, Rheumatology, Immunology, Blood tests, Ferritin, Iron metabolism, Monoclonal antibody, AOSD, Arthritis, Periodic fever syndrome

The Company anticipates initial data to be reported in the third quarter of 2021.\nCERC-007 is a high affinity, fully human anti-IL-18 monoclonal antibody (mAb).

Key Points: 
  • The Company anticipates initial data to be reported in the third quarter of 2021.\nCERC-007 is a high affinity, fully human anti-IL-18 monoclonal antibody (mAb).
  • IL-18 has been demonstrated to have a key role as a marker of disease activity and its concentration correlates with disease severity in AOSD patients.
  • AOSD is a rare auto-inflammatory disease associated with fever, rash, pharyngitis, arthritis, liver disease, and increased ferritin.
  • The primary objective of the study will be to determine the safety and tolerability of CERC-007 in AOSD patients.

Nemysis Ltd Establishes a New Subsidiary in the U.S.

Retrieved on: 
Wednesday, April 7, 2021
Blood, Branches of biology, Hematology, Mineral deficiencies, Iron metabolism, Anemias, Iron deficiency, Ferritin, Iron

We will bring innovative treatments to patients with nutritional deficiencies, and serve our existing and future principals in the best possible way.

Key Points: 
  • We will bring innovative treatments to patients with nutritional deficiencies, and serve our existing and future principals in the best possible way.
  • Zachary Dutton, CEO of Enteralia Bioscience added: "I am thrilled we are establishing Enteralia Bioscience LLC.
  • The U.S. and Boston area, in particular, is home to one of the most advanced scientific and medical communities.
  • Nemysis's novel nanoparticulate iron is the first natural ferritin mimic, which can correct human iron deficiency and anemia, without negatively impacting the gut microbiome.

This Earth Day, The Lucky Iron Fish is the sustainable, eco-friendly cooking tool that is clinically proven to improve iron levels.

Retrieved on: 
Thursday, March 4, 2021
Chemistry, Physical sciences, Metals, Cast iron, Iron metabolism, Lucky iron fish, Iron, Cooking, Sustainability

Lucky Iron Fish is a cooking tool that adds a natural boost of iron into your diet.

Key Points: 
  • Lucky Iron Fish is a cooking tool that adds a natural boost of iron into your diet.
  • Making its innovation accessible to communities in need is a core value of Lucky Iron Fish.
  • The Lucky Iron Fish was officially founded by Dr. Gavin Armstrong after years of doctorate research from Guelph University.
  • If you are working on eco-friendly, sustainable roundups or seeking an expert source for your Earth Month articles, please consider including Lucky Iron Fish.

CANADIAN HEALTH INNOVATORS, LUCKY IRON FISH ENTERPRISE, EXPAND THEIR PRESENCE IN MAINLAND CHINA

Retrieved on: 
Wednesday, March 3, 2021
Chemistry, Physical sciences, Natural sciences, Iron metabolism, Cast iron, Lucky iron fish, Mineral deficiencies, Iron deficiency, Physiological plant disorders, Iron

Toronto, ON, March 03, 2021 (GLOBE NEWSWIRE) -- Lucky Iron Fish Enterprise (LIFe) , a Canadian social enterprise that is committed to tackling iron deficiency, is pleased to announce that, after months of preparation, it has officially expanded its presence into Mainland China.

Key Points: 
  • Toronto, ON, March 03, 2021 (GLOBE NEWSWIRE) -- Lucky Iron Fish Enterprise (LIFe) , a Canadian social enterprise that is committed to tackling iron deficiency, is pleased to announce that, after months of preparation, it has officially expanded its presence into Mainland China.
  • LIFes simple cooking tools, Lucky Iron Fish and Lucky Iron Leaf, make it easy for families to enrich meals with a boost of natural iron for many years.
  • The company is currently selling its original product, Lucky Iron Fish, on Tmall Global but will be introducing its other product, the Lucky Iron Leaf , during phase two of the expansion.
  • Lucky Iron Fish is a clinically proven cooking tool that infuses meals with iron to help treat and prevent iron deficiency.